Global Uterine Fibroids Treatment Market - 2025-2033

The global uterine fibroids treatment market size reached US$ 1.58 billion in 2024 and is expected to reach US$ 3.57 billion by 2033, growing at a CAGR of 9.5% during the forecast period 2025-2033.

Uterine fibroids (also called leiomyomas) are growths made of muscle and tissue that form in or on the wall of the uterus. These growths are usually benign and are the most common noncancerous tumors in females. Uterine fibroids can cause a variety of symptoms like pain and heavy, irregular vaginal bleeding. Sometimes, a person has no symptoms and is unaware they have fibroids. Treatment for fibroids typically depends on the severity of the symptoms.

Fibroids can grow as a single nodule (one growth) or in a cluster. Clusters of fibroids can range in size from 1 millimeter to more than 20 centimeters (8 inches) in diameter or even larger. For comparison, fibroids can be as small as a seed or as large as a watermelon. These growths can develop within the wall of the uterus, inside the main cavity of the uterus, or on the outer surface of the uterus.

Market Dynamics: Drivers & Restraints

Rising advancements in treatment options are significantly driving the uterine fibroids treatment market growth.

Advancements in treatment options are one of the key drivers of growth in the uterine fibroids market. These innovations offer safer, more effective, and minimally invasive alternatives to traditional treatments, providing numerous benefits for patients, including reduced recovery time, lower complication rates, and better outcomes. New drugs like Myfembree and Yselty have been approved to treat fibroids by reducing the hormone levels that contribute to fibroid growth. These oral medications provide a non-invasive alternative to surgery.

For instance, in August 2022, Myovant Sciences and Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) approved MYFEMBREE (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) as a one-pill, once-a-day therapy for the management of moderate to severe pain associated with endometriosis in pre-menopausal women, with a treatment duration of up to 24 months. MYFEMBREE is also approved for heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women.

Additionally, in June 2022, the European Commission (EC) granted Marketing Authorization for Yselty (linzagolix), an oral GnRH antagonist, indicated for the treatment of moderate to severe symptoms of Uterine Fibroids (UF) in adult women (over 18 years of age) of reproductive age.

Limited awareness and delayed diagnosis hamper the market growth

Limited awareness and delayed diagnosis are significant factors that hamper the growth of the uterine fibroids treatment market. Many women are unaware of the condition, its symptoms, and available treatments, which often leads to late-stage diagnosis and treatment. This creates barriers to market growth.

Many women do not recognize the symptoms of uterine fibroids, such as heavy menstrual bleeding, pelvic pain, and frequent urination. This lack of awareness results in late diagnosis, often when the fibroids have grown larger or become more complicated to treat. For instance, according to the American College of Obstetricians and Gynecologists, studies suggest that up to 60% of women with uterine fibroids are unaware that they have them until they experience severe symptoms.

By the time fibroids are diagnosed, many women may require more invasive or complex treatments, such as a hysterectomy, which could have been avoided with earlier intervention. When women do not seek medical advice on time, they miss the opportunity for early-stage treatments like uterine artery embolization (UAE) or myomectomy, which could be less invasive and more effective in preserving fertility and overall health.

Segment Analysis

The global uterine fibroids treatment market is segmented based on type, treatment, and region.

Treatment:

The surgical treatment segment is expected to dominate the uterine fibroids treatment market with the highest market share.

Surgical treatment remains an effective treatment for uterine fibroids, primarily due to its high efficacy in completely removing fibroids, providing long-term relief from symptoms, and widespread availability. The best treatment for uterine fibroids depends on individual factors, but options range from medication to surgery, with myomectomy (surgical removal of fibroids) being a common choice for those wanting to preserve their uterus, and hysterectomy (removal of the uterus) for those who don't want to get pregnant in the future.

The only permanent solution for uterine fibroids, that it eliminates the possibility of fibroid recurrence. Recommended for women experiencing severe symptoms (e.g., heavy menstrual bleeding, chronic pelvic pain) who do not plan to conceive. For instance, the National Uterine Fibroids Foundation states that a hysterectomy is performed in 30-40% of fibroid cases due to its definitive nature. Over 200,000 hysterectomies are performed annually in the U.S. due to fibroids, making it one of the most common surgical procedures among women.

Geographical Analysis

North America is expected to hold a significant position in the global uterine fibroids treatment market with the highest market share

Uterine fibroids affect 60-80% of women of reproductive age, and the condition is particularly prevalent among African American women, with studies showing that African American women are 2-3 times more likely to develop fibroids compared to Caucasian women. For instance, according to the Centers for Disease Control and Prevention (CDC), uterine fibroids are one of the most common reasons for hysterectomies in the United States, with about 200,000 surgeries performed annually for fibroids. In the United States, nearly 1 in 5 women are affected by uterine fibroids during their lifetime, driving high demand for treatment options.

North America benefits from some of the best healthcare facilities in the world, including specialized centers for gynecology and women's health, which are equipped with state-of-the-art medical technologies for diagnosing and treating uterine fibroids. For instance, the Cleveland Clinic, Johns Hopkins Medicine, and other prominent hospitals offer minimally invasive surgeries like robotic-assisted myomectomy and MRI-guided Focused Ultrasound (MRgFUSl), positioning the region at the forefront of fibroid treatment innovation.

There has been a growing focus on women's reproductive health in North America, resulting in increased awareness about uterine fibroids and their associated symptoms, including heavy bleeding, pelvic pain, and infertility. This has led to more women seeking medical care and treatment options. For instance, in 2021, the Fibroid Foundation in the U.S. conducted awareness campaigns that helped highlight the impacts of uterine fibroids, raising awareness among women and encouraging early diagnosis and treatment.

Competitive Landscape

Top companies in the uterine fibroids treatment market include AbbVie Inc., Pfizer Inc., AstraZeneca, Kissei Pharmaceutical Co., Ltd., and Theramex, among others.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyze product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: This covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyze competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global uterine fibroids treatment market report delivers a detailed analysis with 39 key tables, more than 41 visually impactful figures, and 198 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.